CHMP recommends EU approval of Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive careMore than half of people with early-stage NSCLC experience disease recurrence following surgery,1 and most of these recurrent tumours are metastatic, making them incurable2-7If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Commi...
Source: Roche Investor Update - April 22, 2022 Category: Pharmaceuticals Source Type: news
Boosting Responses to Neoadjuvant Therapy in Resectable NSCLC
(MedPage Today) -- NEW ORLEANS -- Neoadjuvant combinations involving durvalumab (Imfinzi) plus novel agents led to major pathological responses (MPRs) in nearly a third of patients with early-stage non-small cell lung cancer (NSCLC), a phase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 12, 2022 Category: Hematology Source Type: news
AACR: Adding Nivolumab to Neoadjuvant Chemo Slows Resectable NSCLC
TUESDAY, April 12, 2022 -- Neoadjuvant nivolumab plus chemotherapy results in significantly longer event-free survival and increased pathological response among patients with resectable non-small cell lung cancer (NSCLC) compared with chemotherapy... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2022 Category: Pharmaceuticals Source Type: news
Preop Nivoulmab Plus Chemo'a Quantum Leap' in NSCLC Therapy Preop Nivoulmab Plus Chemo'a Quantum Leap' in NSCLC Therapy
Further data from the pivotal Checkmate 816 trial continue to support the combination of nivolumab with chemotherapy in the neoadjuvant setting for patients with resectable non –small cell lung cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 12, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Preop Nivolumab Plus Chemo'a Quantum Leap' in NSCLC Therapy Preop Nivolumab Plus Chemo'a Quantum Leap' in NSCLC Therapy
Further data from the pivotal Checkmate 816 trial continue to support the combination of nivolumab with chemotherapy in the neoadjuvant setting for patients with resectable non –small cell lung cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 12, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Neoadjuvant Nivolumab a 'New Standard' in Lung Cancer
(MedPage Today) -- NEW ORLEANS -- The addition of the immune checkpoint inhibitor nivolumab (Opdivo) to neoadjuvant chemotherapy substantially improved event-free survival (EFS) in patients with operable non-small cell lung cancer (NSCLC), the... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 12, 2022 Category: Hematology Source Type: news
Chemo and RT Before Surgery Boosts Pancreatic Cancer Survival Chemo and RT Before Surgery Boosts Pancreatic Cancer Survival
Long-term results from the Dutch PREOPANC trial confirm that neoadjuvant chemoradiotherapy conveys a survival advantage to patients with resectable and borderline resectable pancreatic cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 10, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
U.S. Food and Drug Administration Approves Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
Approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer1
In the Phase 3 CheckMate -816 trial, Opdivo plus platinum-doublet chemotherapy significantly improved event-free survival and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 7, 2022 Category: Drugs & Pharmacology Source Type: news
FDA Approves Neoadjuvant Nivolumab/Chemo for Early-Stage NSCLC FDA Approves Neoadjuvant Nivolumab/Chemo for Early-Stage NSCLC
The pathologic complete response rate was 24% versus 2.2% with chemotherapy alone.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 5, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 4, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Neoadjuvant Chemo New SOC Option in Urothelial Carcinoma Neoadjuvant Chemo New SOC Option in Urothelial Carcinoma
Neoadjuvant chemotherapy in the high-risk population demonstrated favorable pathologic responses, and was well tolerated.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 24, 2022 Category: Surgery Tags: Hematology-Oncology News Source Type: news
Therapeutic Lymph Node Dissection May Not Be Needed in Melanoma When Index Node Responds Therapeutic Lymph Node Dissection May Not Be Needed in Melanoma When Index Node Responds
In patients with high-risk melanoma who show a robust response to neoadjuvant checkpoint inhibition in the index lymph node, a therapeutic lymph node dissection may be omitted, a retrospective study suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 16, 2022 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Neoadjuvant Therapy in Resectable Pancreatic Cancer Neoadjuvant Therapy in Resectable Pancreatic Cancer
This article reviews the most recent literature.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 15, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Baheya Foundation explores AI to predict response to breast cancer treatment
The Egyptian non-profit has teamed up with GE Healthcare to utilise AI to assess how well a patient is responding to neoadjuvant therapy, commonly used prior to surgery. (Source: mobihealthnews)
Source: mobihealthnews - February 14, 2022 Category: Information Technology Source Type: news
